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Abstract
Background: Fish protein hydrolysates are suggested to contain bioactive sequences capable of affecting met-
abolic pathways involved in the regulation of glucose metabolism and body weight when consumed in low 
doses. Modulation of the appetite-regulating hormone ghrelin may explain suppression of insulin secretion 
and weight loss observed in previous studies with fish protein hydrolysates.
Objective: This study aimed to assess the effect of a single, low dose of cod protein hydrolysate (CPH) before a break-
fast meal on postprandial acylated ghrelin concentration and sensations associated with appetite in healthy subjects.
Design: In this explorative trial with a crossover design, 41 healthy individuals (15 males and 26 females, age 
51 ± 6 years) completed 2 study days separated by 4–7 days of washout. On both study days, a test drink 
containing 20 mg CPH or casein (control) per kg body weight was given immediately before a standardized 
breakfast meal. Acylated ghrelin concentrations were measured before test drink/breakfast (baseline) and at 
time 0, 20, 40, 80, and 180 min postprandially. Sensations associated with appetite were measured by a Visual 
Analog Scale (100 mm) at baseline and 0, 20, 40, and 180 min postprandially.
Results: Statistically, no difference was observed between CPH and control for postprandial acylated ghrelin con-
centrations (mean difference geometric mean: 1.05 pg/mL, 95% confidence interval [CI]: 0.97–1.13, P = 0.266), 
or between the total area under the curve (tAUC) for acylated ghrelin after CPH (tAUC = 17518 pg/mL × min, 
95% CI: 0–47941) and control (tAUC = 17272 pg/mL × min, 95% CI: 0–48048, P = 0.991). No differences were 
found between CPH and control for sensation of appetite, according to tAUC of postprandial scores for satiety 
(P = 0.794) and the feeling of fullness (P = 0.996).
Conclusion: We did not find an effect of a single dose of CPH on postprandial concentrations of acylated 
ghrelin or sensations related to feeling of hunger, compared to control. Further studies should aim to evaluate 
the effect of a supplement with CPH given daily over a period of time.
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Popular scientific summary
• Ghrelin is an appetite-regulating hormone, with high concentrations before a meal and reduced 
concentrations after a meal. Compounds with the ability to suppress the action of ghrelin may be 
valuable for weight regulation.
• Fish protein hydrolysates are suggested to contain bioactive peptides capable of affecting glucose 
metabolism and body weight.
• In this study, no effect of a supplement with cod protein hydrolysate on postprandial ghrelin con-
centrations or sensations related to appetite was observed.
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Ghrelin is a gastric hormone, capable of stimulat-ing hunger and influence energy homeostasis (1). It is a small peptide consisting of 28 amino acids, 
secreted from neuroendocrine cells in the submucosal 
layer of the stomach (2). The circulating ghrelin concen-
tration gradually increases before a meal and decreases 
with feeding (3). Two forms of ghrelin are present in the 
circulation, acylated and non-acylated ghrelin, of which 
the acylated form is the one known to activate the ghrelin 
receptor (2).
Acylated ghrelin is a natural ligand binding to the 
growth hormone secretagogue (GHS) receptor, leading 
to stimulation of the secretion of growth hormone (GH), 
reduction in insulin secretion and glucose tolerance (4–6). 
Furthermore, it has been shown that acylated ghrelin holds 
potent adipogenic and orexigenic effects mediated through 
the GHS receptor located in the central nervous system 
(CNS) (4). Acylated ghrelin is known to directly activate 
pathways in the CNS controlling both parasympathetic 
and sympathetic nerve activity through GHS receptors 
(7) and possibly indirectly suppresses insulin secretion via 
neural signaling (8). These qualities have created the idea 
that compounds having the ability to suppress the action 
of ghrelin may be valuable for the prevention or treatment 
of overweight, obesity, insulin resistance, and abnormal 
lipid and glucose metabolism (9, 10).
In previous studies in rats and humans, it has been ob-
served that the intake of low doses of peptides from fish 
is capable of beneficially influencing glucose metabolism 
(11–14), reducing adipose tissue mass, and improving 
serum fatty acid composition (15, 16), when compared to 
placebo or casein. In addition, some recent studies have 
found fish protein hydrolysates to beneficially influence hor-
mones involved in the regulation of appetite, such as cho-
lecystokinin (CCK) and glucagon-like peptide 1 (GLP-1), 
as well as influence the subjective feeling of craving sweets 
(17, 18), when compared to placebo in human subjects. The 
suggested effective daily dose based on the current litera-
ture in human subjects ranges from 1 to 6 g per day (13, 18). 
Consequently, the hypothesized effect of a fish protein hy-
drolysate is not due to the consumed protein per se, which 
is negligible compared to the normal recommended total 
daily dietary intake of a healthy individual (e.g. 65–80 g 
protein per day with body weight 80 kg) (19). A possible 
mechanism for suppression of postprandial insulin concen-
tration and weight loss could be modulation of postpran-
dial ghrelin concentrations, and a low dose of fish protein 
hydrolysate is presumed to be effective due to the content of 
bioactive peptides with unique amino acid sequences (20). 
In the current trial, we hypothesize that a potential sup-
pressing effect on appetite and postprandial ghrelin levels 
can be attributed to a high fraction of di- and tripeptides 
with branched-chain amino acids in the cod protein hy-
drolysate (CPH), facilitating rapidly absorption from the 
gastrointestinal tract and possibly capable of influencing 
pathways involved in the regulation of appetite.
As metabolism and energy expenditure decrease with 
age, middle-aged individuals often experience weight 
gain. Thus, middle-aged individuals might benefit from 
an intervention targeting appetite and hunger regulation. 
Data on the specific effect of a dietary supplement with 
a fish protein hydrolysate on ghrelin concentrations and 
sensations associated with appetite have, to our knowl-
edge, previously not been published. The present study 
aimed to assess the effect of a single, low dose of CPH 
before a breakfast meal on postprandial acylated ghrelin 
concentration and sensations associated with appetite in 
healthy, middle-aged to elderly subjects.
Material and methods
Data on subjects and methods have been described in de-
tail in a previous publication (14).
Trial design
The study was a double-blind crossover trial, which in-
cluded two study visits for each subject, with 4–7 days of 
washout in between. The intervention included serving 
of a test drink containing 20 mg of CPH per kg body 
weight (test material) or control (casein) in randomized 
order, immediately before a standardized breakfast meal 
was served. The CPH and casein powder were mixed with 
cold water and served as a drink. The primary outcome of 
the intervention (postprandial response in glucose metab-
olism) is reported in a previous publication (14). Here, we 
report the secondary outcome: acylated ghrelin concen-
trations measured for 180 min postprandially and subjec-
tive sensations associated with appetite.
This study was conducted according to the guidelines 
laid down in the Declaration of Helsinki, and all pro-
cedures were approved by the Regional Committees for 
Medical and Health Research Ethics of Central Norway 
(2017/1794). Written informed consent was obtained from 
all subjects. The trial was registered at clinicaltrials.gov as 
NCT03669796.
Participants
Subjects were recruited at Haukeland University Hospital 
and Ålesund Hospital between October 2017 and February 
2018. Potential subjects were interviewed for general 
eligibility and compliance with inclusion and exclusion 
criteria by telephone. Candidates were invited for a fur-
ther screening visit.
Inclusion criteria were as follows: age 40–65 years and 
body mass index (BMI) 20–30 kg/m2. Exclusion criteria 
were fish allergy, pharmacologically treated diabetes mel-
litus, elevated blood pressure, chronic diseases that might 
affect the evaluation of the study endpoints, and acute 
infections.
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Study protocol
The screening visit included a clinical examination 
by a physician, biochemistry tests for safety purposes 
(leukocyter, trombocytes, hemoglobin, fasting glucose, 
long-term blood glucose, C-reactive protein, creatinine, 
sodium, potassium, kidney function estimate, liver en-
zymes and muscle enzymes) and compliance with in-
clusion criteria, measuring of  height, weight, and blood 
pressure, as well as assessment of  the level of  physical 
activity. The level of  physical activity was assessed by 
asking the participants two questions regarding moder-
ate physical activity and vigorous activity (self-reported). 
The participants were instructed not to change the diet 
composition or the level of  physical activity during the 
study period. On the day preceding each study day, the 
participants received a standardized porridge evening 
meal to be eaten before 8:30 pm. After this, the subjects 
were instructed to fast until the next morning and were 
only allowed to drink water. On study days, the partici-
pants came to the research units in a fasting state between 
08:00 am and 09:00 am. After the first blood sample, the 
subjects were served the test drink, before the breakfast 
meal was provided. Fifteen minutes after the breakfast 
was served, the first post-meal sample (0 min sample) was 
taken.
The standardized breakfast meal consisted of two slices 
of bread (50% whole wheat, 80 g bread), 10 g margarine, 
20 g strawberry jam, and 20 g white cheese. This provided 
a total of 355 kcal (1,485 kJ, 41 g carbohydrate, 12.5 g 
protein, 15 g fat). The drink contained on average 35.9 g 
carbohydrate and 145 kcal (607 kJ). Thus, including the 
drink, the breakfast provided in total 500 kcal (2,092 kJ) 
and 77 g carbohydrate, equal at both study days. Water 
was given ad libitum, but no coffee or tea was allowed. 
The subjects spent 4 h in the research units, and repeated 
sampling of blood was conducted before serving of the 
test drink and breakfast, and at time 0, 20, 40, 80, and 
180 min postprandially.
Assessments
Assessment of medical history, measurement of biochem-
ical variables and safety parameters were conducted be-
fore randomization. During the two study visits, acylated 
ghrelin was measured in plasma samples taken before 
serving of the test drink and breakfast (baseline), at time 
0, 20, 40, 80, and 180 min postprandially. The subjects 
had 15 min to finish the breakfast before the 0 min sam-
ple was taken. Blood pressure was measured before inter-
vention, after 40 and 180 min after the intervention, as a 
safety parameter.
Appetite sensation was assessed on a Visual Analog 
Scale (VAS) of 100 mm in length, addressing the feeling 
of fullness and satiety. The VAS questionnaire also in-
cluded three questions regarding adverse gastrointestinal 
symptoms (pain, discomfort, and nausea). The VAS was 
filled out five times during the study visit, at baseline, time 
0 and 20, 40, and 180 min after the breakfast meal. Ad-
ditionally, a questionnaire validated for the evaluation of 
different gastrointestinal symptoms was filled out before 
the breakfast meal and at the end of each study day (21). 
The questionnaire assessed nausea, bloating, stomach 
pain, constipation, and diarrhea, as well as hunger/satiety 
with a score from 0 to 10, of which the score 10 indicated 
severe symptoms and being fully satiated.
Test materials
The test material was a lemon-flavored powder provided 
from the manufacturer (Firmenich Bjørge Biomarin AS, 
Ålesund, Norway) in standardized bottles to be added 
150 mL cold water. The powder contained 4% protein 
(CPH raw material or whole casein) and 96% carbohy-
drate (maltodextrin). Thorough laboratory tests assured 
that it was not possible to identify the active ingredient 
from the control, according to flavor or appearance. Each 
subject was given individually adjusted doses of  20 mg/
kg body weight of  CPH or casein. The drinks were made 
isonitrogenous to avoid bias due to difference in nitro-
gen content, and equal amounts of  nitrogen in the form 
of casein were added to the control drink. Both drinks 
contained on average 1.6 g protein; thus it constituted 
only a small fraction of the total protein content of  the 
standardized breakfast meal. Casein was chosen as the 
control as it has previously shown to not affect blood glu-
cose or insulin sensitivity when compared with proteins 
from cod and soya (22). The casein used as control was 
present as whole protein and did not contain free amino 
acids or peptides. The production and composition of 
the test  materials has been described in detail in previous 
publication (14).
Analysis of blood samples
Samples of venous blood were repeatedly collected using 
an intravenous catheter from the antecubital vein. Sam-
ples were analyzed according to standard accredited 
methods at the Laboratory for Clinical Biochemistry, 
Haukeland University Hospital (Bergen, Norway) and 
the Department of Medical Biochemistry, Ålesund Hos-
pital (Ålesund, Norway).
Plasma ghrelin was obtained by centrifugation of full 
blood using 4 mL anticoagulant (EDTA-K3)/Aproti-
nin blood collecting tubes (VACUETTE®, Greiner Bio 
One International GmbH, cat # 454261, Kremsmünster, 
Austria) at 1800 × g at 4°C for 10 min within 20 min after 
blood sampling. Plasma was stored frozen at −80°C prior 
to analysis. The ghrelin analyses were performed using 
Acylated Ghrelin-Easy Sampling Enzyme Immunoassay 
kit (Bertin Pharma, Montigny-le-Bretonneux, France, ref: 
#A11306).
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Statistical analysis
SPSS data package (SPSS Statistics 24.0, IBM Company, 
Armonk, NY, USA) and GraphPad Prism version 7.0 
(GraphPad Software, Inc., San Diego, CA, USA) were 
used for statistical analysis. Shapiro–Wilk’s test was con-
ducted to assess normal distribution of data. A multivari-
able, repeated-measures linear mixed-effects regression 
analysis (adjusted for BMI and gender) was conducted 
in SPSS in order to evaluate the difference between the 
concentrations of acylated ghrelin after CPH and control. 
The data for acylated ghrelin were non-normally distrib-
uted; thus, it was log-transformed before analysis and 
presented as log mean and back-transformed values (geo-
metric means). Graphical work and total area under the 
curve (tAUC) analysis for acylated ghrelin concentrations 
and symptom VAS-scores were conducted in GraphPad. 
The difference in baseline and end-point scores for the 
additional questionnaire was evaluated by a paired t-test. 
Assessment of correlations was done with Pearson’s cor-
relation coefficient. P-values < 0.05 were considered statis-
tically significant.
The number of participants was not calculated accord-
ing to a power analysis, due to lack of similar studies. 
Previous research reporting on effect of cod proteins in 
humans is based on whole fish (23) or long-term use of 
fish protein supplement (12, 13); thus, we did not find any 
data suitable as basis for power analysis for our design.
Results
Subjects
Seventy-eight subjects were screened for inclusion and ex-
clusion criteria over telephone, of which 47 were enrolled 
to a screening visit. Six participants withdrew before the 
first study visit, and 41 participants completed the trial, of 
which 15 males and 26 females. The inclusion process has 
previously been described and illustrated (14). The mean 
age of the participants was 51 ± 6 years (range 40–64 
years). The mean body weight of the participants was 
77.3 ± 13.5 kg. Dependent on body weight, the subjects 
consumed CPH in a dose ranging from 1.2 to 2.3 g (mean 
1.5 g). Mean BMI was 25.2 ± 3 kg/m2. Twenty-three par-
ticipants had BMI ≤ 25 kg/m2, whereas 18 participants 
had BMI > 25 kg/m2. Baseline characteristics and com-
parison of gender distribution are presented in Table 1.
Acylated ghrelin concentrations
Mean fasting acylated ghrelin levels were higher before 
the CPH intervention than before the control interven-
tion (97.4 ± 196.3 pg/mL vs. 90.0 ± 194.0 pg/mL, respec-
tively), but the difference was not significant (P > 0.999). 
Suppression of acylated ghrelin (Cmin) was greatest: 80 
min postprandially after CPH and 20 min postprandially 
after control, with a Cmin mean difference from baseline of 
−14.0 ± 21.4 after CPH and −5.3 ± 22.8 after control, at 
these times, respectively (P = 0.681).
Statistically, no differences were observed between CPH 
and control for postprandial acylated ghrelin concentra-
tion in a mixed-effects regression analysis (mean differ-
ence of the geometric mean: 1.05 pg/mL, 95%  confidence 
interval [CI]: 0.97–1.13, P = 0.266) (Fig. 1). Additionally, 
Table 1. Baseline characteristics of the 41 participants (26 females and 15 males) included in the study at the Haukeland University Hospital 
and Ålesund Hospital
Characteristics Total subjects (n = 41) Female (n = 26) Male (n = 15) P
Mean Standard deviation Mean Standard deviation Mean Standard deviation
Age, years 51.0 6.0 52.1 6.2 49.0 5.0 0.104
Body weight 77.3 13.5 71.6 10.8 87.2 12.3 0.001
Body mass index, kg/m2 25.2 3.0 24.7 3.0 26.0 2.9 0.183
Acylated ghrelin, pg/mL 93.7 194.9 81.4 184.7 115.0 210.6 0.453
Baseline acylated ghrelin concentrations are merged values for the baseline value at both study visits.
Fig. 1.  Metabolic response in acylated ghrelin concentration 
after intake of a standardized breakfast meal supplemented 
with a drink containing a cod protein hydrolysate (CPH) or 
control (casein). Results are presented for 41 healthy sub-
jects. Time point 0 min shows values measured right after 
the intake of breakfast and test drink. Values are presented 
as mean + SD. Statistically, no differences were observed be-
tween CPH and control for acylated ghrelin concentration in 
a mixed-model regression analysis (P = 0.266).
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no difference was observed between the tAUC for acylated 
ghrelin concentrations after CPH (tAUC = 17518  pg/
mL  × min, 95% CI: 0–47941) and control (tAUC  = 
17272 pg/mL × min, 95% CI: 0–48048, P = 0.991).
No correlation was observed between body weight 
(kg) and baseline concentration of acylated ghrelin 
(mean baseline value before CPH and control) (r = 0.118, 
P = 0.463). When adjusting for BMI and gender in the 
mixed-effects regression analysis, no differences were ob-
served between subjects with BMI ≤ 25 kg/m2 compared 
to those with BMI > 25 kg/m2 (P = 0.681), or between 
genders (P = 0.627).
Sensation of appetite 
Baseline scores for satiety were numerically the same 
before each intervention (CPH: 37.4 ± 26.6, control: 
35.1 ± 23.9, P = 0.997). No difference was observed 
between the tAUC for the postprandial satiety scores 
after CPH (tAUC = 10989 mm × min, 95% CI: 6794–
15185) and control (tAUC = 11742 mm × min, 95% CI: 
8001–15483, P = 0.794). Data are presented in Fig. 2a.
Baseline scores for the feeling of  fullness were 
numerically the same before each intervention (CPH: 
7.1 ± 15.7, control: 7.3 ± 17.5, P > 0.999). No differ-
ence was observed between the tAUC for the post-
prandial feeling of  fullness scores after CPH (tAUC = 
1306 mm × min, 95% CI: 0–3257) and control (tAUC = 
1243 mm × min, 95% CI: 0–3418, P = 0.966). Data are 
presented in Fig. 2b.
The questionnaire addressing hunger did not reveal any 
differences in the feeling of satiety and hunger between 
CPH (3.4 ± 1.8) and control (3.4 ± 2.3) 180 min after the 
breakfast (P = 0.822). Baseline scores did not differ before 
each intervention (CPH: 3.7 ± 2.7 and control: 3.0 ± 2.5, 
P = 0.165).
Gastrointestinal symptoms
There were no reports of adverse gastrointestinal symp-
toms (e.g. nausea, bloating, stomach pain, constipation, or 
diarrhea) during the exposure for either CPH or control.
Discussion
This study revealed no differences in postprandial con-
centrations of acylated ghrelin after a meal supplemented 
with CPH compared to control. Thus, we were unable to 
confirm our hypothesis that a single dose of CPH sup-
plementation before a meal would suppress ghrelin con-
centrations postprandially, and thereby cause reduced 
feeling of hunger. Moreover, we found no differences 
between control and CPH drink in the feeling of satiety 
or feeling of fullness, as measured by the implemented 
questionnaires.
In a previous publication, we reported that supple-
mentation with 20 mg CPH per kg body weight before a 
breakfast meal reduced the postprandial concentrations 
of  insulin compared to control in healthy individuals 
(14). Although not affecting glucose levels or concen-
trations of  GLP-1, we found that pre-prandial supple-
mentation with one low dose of  CPH may beneficially 
alter the glucose metabolism. An inverse correlation be-
tween postprandial insulin concentrations and plasma 
ghrelin has previously been reported (24), and changes 
in ghrelin concentration after CPH might affect post-
prandial insulin secretion. The major effects of  ghrelin 
are linked to mechanisms involved in avoiding starvation 
and promoting food intake and include stimulation of 
GH secretion to restrict peripheral glucose uptake, pro-
mote lipolysis, and suppress insulin secretion to prevent 
hypoglycemia (25). Due to this close link between glu-
cose metabolism and appetite control, it can be hypoth-
esized that supplementation with CPH might influence 
Fig. 2.  Symptom scores from a VAS-questionnaire addressing satiety (a) and the feeling of fullness (b) after intake of a stan-
dardized breakfast meal supplemented with a drink containing either a cod protein hydrolysate (CPH) or control (casein). 
 Results are presented for 41 healthy subjects. Time point 0 min shows values measured right after the intake of breakfast and test 
material. Values are presented as mean + SD. Statistically, no differences were found between CPH and control for sensation of 
appetite, according to the tAUC of postprandial scores for satiety (P = 0.794) and the feeling of fullness (P = 0.966).
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postprandial ghrelin concentrations and the feeling of 
hunger and satiety.
Our results are partly in line with previous similar sin-
gle-dose studies; however, few studies are comparable in 
test material. Most studies investigating the relationship 
between ghrelin levels after meals with different macro-
nutrient composition have found that a high-protein meal 
causes the ghrelin levels to be suppressed for a longer 
time than after the intake of a meal high in carbohydrates 
(26–31). Furthermore, it causes higher satiety scores post-
prandially than a meal containing regular or low amount 
of protein (28, 32). The mechanisms suggested to facil-
itate these findings include slowing of gastric emptying, 
increase of plasma insulin, glucagon, ghrelin, CCK, 
gastric inhibitory polypeptide (GIP), and GLP-1 after a 
high-protein meal (33).
Only a few studies have reported on the specific acute 
postprandial effect of a meal with proteins from fish, 
compared to other protein sources (34–36). A compari-
son of the effects of isocaloric meals with proteins from 
beef, chicken, or fish revealed a significantly higher satiety 
score after the fish meal compared to the other protein 
sources (34). A study evaluating the effect on satiety when 
comparing a fish protein meal with a beef protein meal 
revealed that subjects receiving the fish-meal had lower 
hunger scores and consumed less energy in the subsequent 
evening meal (36). In contrast, a study investigating the 
acute effect of meals based on proteins from cod or veal 
in combination with carbohydrates high- or low-glycemic 
index did not find any differences in appetite sensation, 
energy intake, or postprandial response in glucose, insu-
lin, or ghrelin levels when comparing the two different 
protein sources (35). Although some previous studies have 
reported fish proteins to suppress appetite, no effect has 
this far been reported for the levels of ghrelin. One previ-
ous study has reported on the specific hunger-regulating 
effect of a fish protein hydrolysate from blue whiting 
(2 g/day) (17). The fish protein hydrolysate was reported to 
suppress appetite when compared to placebo in a 2-week 
crossover trial in overweight women. According to post-
prandial measures after a standardized breakfast meal, it 
was observed that the fish protein hydrolysate significantly 
reduced sweet-cravings, as well as plasma glucose levels 
compared to placebo. This study was based on observa-
tions made in both in vitro and in vivo models, showing 
that the fish protein hydrolysate was capable of enhancing 
the secretion of CCK and GLP-1, both hormones con-
tributing to the regulation of energy intake (37).
In the present study, we hypothesized that a potential 
suppressing effect on appetite and postprandial ghrelin 
levels would occur due to the CPH containing a high frac-
tion of di- and tripeptides with the branched-chain amino 
acids leucine and isoleucine. We hypothesize that these 
peptides work as biologically active substances, which 
are rapidly absorbed from the gastrointestinal tract and 
possibly capable of influencing pathways involved in the 
regulation of appetite. Thus, a single low dose of peptides 
was administered to the participants. The amount of pro-
tein provided was so low that it can be regarded negligible 
per se, compared to the amount of protein provided in 
the breakfast meal. Several factors could explain the lack 
of observed effect. First, it is possible that one acute ex-
posure of the low concentration is not enough to induce 
the wanted effect. A different effect could might have been 
observed if  the participants had taken the CPH supple-
ment daily for a period of time, for instance over a period 
of 6–8 weeks.
A similar dose of  CPH as the one administered in our 
trial, has previously been reported to increase concen-
trations of  CCK and GLP-1 compared to placebo in a 
study including 120 overweight individuals given either 
1.4 or 2.8 g protein hydrolysate from blue whiting or pla-
cebo, for 90 days (18). The fish protein hydrolysate was 
found to be effective compared to placebo, but no differ-
ence in effect was observed between the two doses. This 
demonstrates a potential effect when CPH is adminis-
tered orally in doses of  approximately 15–20 mg per kg 
body weight. In our study, the subjects consumed CPH 
in a dose range from 1.2 to 2.3 g (mean 1.5 g), dependent 
on body weight. Thus, if  an effect was to be observed, 
this could possibly have been attributed to the presence 
of  bioactive peptides.
The results have to be interpreted taking certain 
strengths and limitations into account. First, the random-
ized, crossover design as well as the successful blinding 
with similar test drink and control is a strength of this 
study. Furthermore, the adjustment of peptide dose ac-
cording to the body weight of each participant can be 
regarded as an improvement in accuracy compared to 
previous investigations of protein meals and the few stud-
ies investigating a marine protein hydrolysate, as this may 
reduce the effect of variation in body weight. It can be 
regarded a weakness of the design that the control drink 
contained casein in equal amounts as CPH, and that we 
did not include a true placebo without protein. However, 
as discussed above, the hypothesized effect is attributed 
to the presence of bioactive peptides and not protein per 
se. Whole casein was chosen as control, so the observed 
effect should not be simply due to differences in energy 
and nitrogen content. Casein has previously been shown 
to not affect glucose metabolism when given in low con-
centrations (38). We could arguably have investigated the 
effect of CPH on several different hunger-regulating hor-
mones, for instance, CCK, which has been measured in 
few other studies investigating the effect of a fish protein 
hydrolysate on appetite (17, 18). The assessment of ap-
petite could have been improved by using a more com-
prehensive instrument at all timepoints (39). However, 
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the use of VAS ratings in the evaluation of appetite in 
healthy subjects is a previously validated method (40). An 
ad libitum lunch meal with subsequent calculations of ac-
tual energy intake after CPH and control could have been 
included for a better and more detailed investigation of 
appetite. Furthermore, it is possible that the lack of suffi-
cient previous data to perform a power analysis could re-
sult in too few included participants to be able to observe 
an effect. We decided to include 40 participants, a number 
greater than or equal to previously reported studies on 
cod protein (12, 13, 23).
Further studies should aim to evaluate the impact of 
fish protein hydrolysates on different metabolic pathways 
involved in glucose metabolism and appetite control, such 
as regulation of different hunger-regulating hormones. In 
addition to ghrelin, insulin-like peptide 5 (INSL5) is quite 
recently suggested to be an orexigenic hormone influenc-
ing appetite and regulation of food intake (41). Thus, fu-
ture studies should aim to evaluate the appetite-regulating 
effect of CPH on several hormones, including INSL5. As-
sessments of such response can arguably contribute to the 
expansion of knowledge on the effects of CPH, as well as 
possibly reveal new preventive and treatment options for 
overweight and obesity. Based on the current literature, 
the effect could be more apparent if  the fish protein hy-
drolysate had been given daily over a period of time, and 
if  it had been investigated in a target group of overweight 
and obese individuals.Thus, the design of future studies 
should take this into account.
In conclusion, we did not find any effect of a single 
dose of CPH on postprandial concentrations of acylated 
ghrelin, or sensations-related appetite in healthy individu-
als, when compared to control after a standardized break-
fast meal.
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